title: The effects of indomethacin, NDGA, allopurinol and superoxide dismutase on prostaglandin E2 and leukotriene C4 levels after mesenteric ischemia-reperfusion injury.
abstract: In this study, the changes of arachidonic acid metabolites after an ischemia-reperfusion (I/R) period are investigated. The cyclooxygenase and lipoxygenase metabolites were found to be significantly increased after a 45 min period of ischemia followed by 5 min of reperfusion. Prostaglandin E2 (PGE2)- and leukotriene C4 (LTC4)-like activities did not change in the ischemic period, but they both increased after reperfusion. A cyclooxygenase inhibitor indomethacin and lipoxygenase inhibitor nordehydroguaretic acid (NDGA) decreased PGE2- and LTC4-like activities, respectively, while allopurinol and superoxide dismutase (SOD) decreased both activities. According to our results, it can be assumed that free oxygen radicals are responsible for the elevation of PGE2- and LTC4-like activities and both of these arachidonic acid metabolites and free oxygen radicals are the main necrotizing agents in ischemia-reperfusion induced damage.
authors.affiliation: Inönü University, Faculty of Medicine, Department of General Surgery, Malatya, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Sare
authors.forename: S
authors.initials: S
authors.lastname: Bozkurt
authors.forename: E
authors.initials: E
authors.lastname: Onuk
authors.forename: M
authors.initials: M
authors.lastname: Oguz
authors.forename: M
authors.initials: M
authors.lastname: Gurel
authors.forename: S
authors.initials: S
authors.lastname: Ercan
mesh_terms: D000469:Alkaline Phosphatase / Q000378:metabolism; D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D003402:Creatine Kinase / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000097:blood / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D007213:Indomethacin / Q000494:pharmacology; D007511:Ischemia / Q000188:drug therapy* / Q000378:metabolism; D017997:Leukotriene C4 / Q000097:blood / Q000378:metabolism*; D008297:Male; D009637:Masoprocol / Q000494:pharmacology; D008643:Mesentery / Q000098:blood supply* / Q000187:drug effects / Q000293:injuries; D051381:Rats; D015427:Reperfusion Injury / Q000188:drug therapy / Q000378:metabolism*; D013482:Superoxide Dismutase / Q000494:pharmacology; D015149:Tocolytic Agents / Q000494:pharmacology
chemical_list: D000975:Antioxidants; D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D015149:Tocolytic Agents; D017997:Leukotriene C4; D000493:Allopurinol; D009637:Masoprocol; D013482:Superoxide Dismutase; D003402:Creatine Kinase; D000469:Alkaline Phosphatase; D015232:Dinoprostone; D007213:Indomethacin